CHARM Therapeutics' CEO discusses its DragonFold technology, applying AI to cancer drug hunting, and the benefits of its Nobel Prize-winning roots.

One month after announcing a pipeline pivot, Ovid Therapeutics talked to In Vivo about the importance of making strategic decisions with discipline, and the imminent neurology revolution.

Glen Clova Scientific is galvanizing virus-like particle technology with disruptive advances in manufacturing to treat immune-related dermatology conditions in often overlooked senile populations.

As pharmaceutical companies face a crowded and competitive landscape, the debate between being first-in-class or best-in-class is evergreen. This strategic choice impacts new product launches, with first-to-market therapies offering market share and brand recognition advantages, while best-in-class options can capture value through product differentiation and commercial execution. In Vivo talked to L.E.K. Consulting on how to make a product stand out from the crowd.

Data provided by Biomedtracker show that data-driven methodologies within R&D are propelling life sciences to unprecedented advancements. It is making drug development faster, more efficient and more personalized.

The financial macroenvironment may be looking more favorable for 2025 but will pharma growth be muted by elements beyond its control? In Vivo discusses the headwinds and drivers for pharma in the coming 12 months.